Build Your Comparison

Side-by-side financial analysis
WAY logo
WAY
HIMS logo
HIMS
JPM logo
JPM
Try popular comparisons:

Stock Comparison

WAY vs HIMS vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
WAY
Waystar Holding Corp.

Information Technology Services

TechnologyNASDAQ • US
Market Cap$3.60B
5Y Perf.-12.8%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$5.89B
5Y Perf.+32.8%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+58.6%

WAY vs HIMS vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
WAY logoWAY
HIMS logoHIMS
JPM logoJPM
IndustryInformation Technology ServicesMedical - Equipment & ServicesBanks - Diversified
Market Cap$3.60B$5.89B$896.00B
Revenue (TTM)$1.16B$2.37B$280.33B
Net Income (TTM)$126M$-13M$57.05B
Gross Margin65.2%67.6%60.0%
Operating Margin24.3%1.3%25.9%
Forward P/E11.4x52.6x14.4x
Total Debt$1.50B$1.26B$942.38B
Cash & Equiv.$61M$229M$343.34B

WAY vs HIMS vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

WAY
HIMS
JPM
StockJun 24Jun 26Return
Waystar Holding Cor… (WAY)10087.2-12.8%
Hims & Hers Health,… (HIMS)100132.8+32.8%
JPMorgan Chase & Co. (JPM)100158.6+58.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: WAY vs HIMS vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: WAY and JPM are tied at the top with 3 categories each — the right choice depends on your priorities. JPMorgan Chase & Co. is the stronger pick specifically for profitability and margin quality and dividend income and shareholder returns. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
WAY
Waystar Holding Corp.
The Income Pick

WAY has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.

  • beta 0.84
  • Lower volatility, beta 0.84, Low D/E 38.7%, current ratio 1.41x
  • Beta 0.84, current ratio 1.41x
Best for: income & stability and sleep-well-at-night
HIMS
Hims & Hers Health, Inc.
The Growth Play

HIMS is the clearest fit if your priority is growth exposure.

  • Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
  • 59.0% revenue growth vs JPM's 3.3%
Best for: growth exposure
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is long-term compounding.

  • 465.8% 10Y total return vs HIMS's 173.7%
  • 20.4% margin vs HIMS's -0.6%
  • 1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs JPM's 3.3%
ValueWAY logoWAYLower P/E (11.4x vs 52.6x)
Quality / MarginsJPM logoJPM20.4% margin vs HIMS's -0.6%
Stability / SafetyWAY logoWAYBeta 0.84 vs HIMS's 2.48, lower leverage
DividendsJPM logoJPM1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)JPM logoJPM+21.8% vs HIMS's -53.1%
Efficiency (ROA)WAY logoWAY2.4% ROA vs HIMS's -0.6%, ROIC 4.2% vs 8.6%

WAY vs HIMS vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the GLP-1 Stocks Theme

These companies are key players in the GLP-1 Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
WAYWaystar Holding Corp.
FY 2025
Subscription and Circulation
100.0%$558M
HIMSHims & Hers Health, Inc.

Segment breakdown not available.

JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

WAY vs HIMS vs JPM — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGHIMS

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 3 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 242.4x WAY's $1.2B. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to HIMS's -0.6%. On growth, WAY holds the edge at +22.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricWAY logoWAYWaystar Holding C…HIMS logoHIMSHims & Hers Healt…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$1.2B$2.4B$280.3B
EBITDAEarnings before interest/tax$430M$99M$81.4B
Net IncomeAfter-tax profit$126M-$13M$57.0B
Free Cash FlowCash after capex$294M$76M$100.9B
Gross MarginGross profit ÷ Revenue+65.2%+67.6%+60.0%
Operating MarginEBIT ÷ Revenue+24.3%+1.3%+25.9%
Net MarginNet income ÷ Revenue+10.9%-0.6%+20.4%
FCF MarginFCF ÷ Revenue+25.4%+3.2%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+22.4%+3.8%
EPS Growth (YoY)Latest quarter vs prior year+37.5%-3.0%+16.0%
JPM leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

WAY leads this category, winning 3 of 6 comparable metrics.

At 16.0x trailing earnings, JPM trades at a 70% valuation discount to HIMS's 52.6x P/E. On an enterprise value basis, WAY's 12.4x EV/EBITDA is more attractive than HIMS's 43.2x.

MetricWAY logoWAYWaystar Holding C…HIMS logoHIMSHims & Hers Healt…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$3.6B$5.9B$896.0B
Enterprise ValueMkt cap + debt − cash$5.0B$6.9B$1.50T
Trailing P/EPrice ÷ TTM EPS30.74x52.59x16.00x
Forward P/EPrice ÷ next-FY EPS est.11.42x14.40x
PEG RatioP/E ÷ EPS growth rate0.90x
EV / EBITDAEnterprise value multiple12.39x43.24x18.36x
Price / SalesMarket cap ÷ Revenue3.27x2.51x3.20x
Price / BookPrice ÷ Book value/share0.95x12.80x2.47x
Price / FCFMarket cap ÷ FCF12.70x79.62x8.88x
WAY leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

Evenly matched — WAY and HIMS each lead in 4 of 9 comparable metrics.

JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-2 for HIMS. WAY carries lower financial leverage with a 0.39x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), WAY scores 5/9 vs HIMS's 4/9, reflecting solid financial health.

MetricWAY logoWAYWaystar Holding C…HIMS logoHIMSHims & Hers Healt…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity+3.5%-2.5%+15.9%
ROA (TTM)Return on assets+2.4%-0.6%+1.3%
ROICReturn on invested capital+4.2%+8.6%+4.5%
ROCEReturn on capital employed+5.2%+9.4%+8.9%
Piotroski ScoreFundamental quality 0–9545
Debt / EquityFinancial leverage0.39x2.34x2.60x
Net DebtTotal debt minus cash$1.4B$1.0B$599.0B
Cash & Equiv.Liquid assets$61M$229M$343.3B
Total DebtShort + long-term debt$1.5B$1.3B$942.4B
Interest CoverageEBIT ÷ Interest expense3.51x0.74x
Evenly matched — WAY and HIMS each lead in 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $9,058 for WAY. Over the past 12 months, JPM leads with a +21.8% total return vs HIMS's -53.1%. The 3-year compound annual growth rate (CAGR) favors HIMS at 44.0% vs WAY's -3.2% — a key indicator of consistent wealth creation.

MetricWAY logoWAYWaystar Holding C…HIMS logoHIMSHims & Hers Healt…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-40.2%-19.7%-0.5%
1-Year ReturnPast 12 months-52.6%-53.1%+21.8%
3-Year ReturnCumulative with dividends-9.4%+198.3%+138.2%
5-Year ReturnCumulative with dividends-9.4%+107.9%+118.2%
10-Year ReturnCumulative with dividends-9.4%+173.7%+465.8%
CAGR (3Y)Annualised 3-year return-3.2%+44.0%+33.6%
JPM leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — WAY and JPM each lead in 1 of 2 comparable metrics.

WAY is the less volatile stock with a 0.84 beta — it tends to amplify market swings less than HIMS's 2.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs HIMS's 38.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricWAY logoWAYWaystar Holding C…HIMS logoHIMSHims & Hers Healt…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5000.84x2.48x0.94x
52-Week HighHighest price in past year$41.47$70.43$337.25
52-Week LowLowest price in past year$17.89$13.74$262.71
% of 52W HighCurrent price vs 52-week peak+45.2%+38.1%+95.1%
RSI (14)Momentum oscillator 0–10040.359.459.1
Avg Volume (50D)Average daily shares traded2.4M24.7M7.0M
Evenly matched — WAY and JPM each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: WAY as "Buy", HIMS as "Hold", JPM as "Buy". Consensus price targets imply 90.0% upside for WAY (target: $36) vs 0.7% for HIMS (target: $27). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.

MetricWAY logoWAYWaystar Holding C…HIMS logoHIMSHims & Hers Healt…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyHoldBuy
Price TargetConsensus 12-month target$35.62$27.00$339.75
# AnalystsCovering analysts172061
Dividend YieldAnnual dividend ÷ price+1.9%
Dividend StreakConsecutive years of raises15
Dividend / ShareAnnual DPS$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.5%+3.9%
Insufficient data to determine a leader in this category.
Key Takeaway

JPM leads in 2 of 6 categories (Income & Cash Flow, Total Returns). WAY leads in 1 (Valuation Metrics). 2 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 2 of 6 categories
Loading custom metrics...

WAY vs HIMS vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is WAY or HIMS or JPM a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — WAY or HIMS or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Hims & Hers Health, Inc. at 52. 6x. On forward P/E, Waystar Holding Corp. is actually cheaper at 11. 4x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — WAY or HIMS or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -9. 4% for Waystar Holding Corp. (WAY). Over 10 years, the gap is even starker: JPM returned +465. 8% versus WAY's -9. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — WAY or HIMS or JPM?

By beta (market sensitivity over 5 years), Waystar Holding Corp.

(WAY) is the lower-risk stock at 0. 84β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 195% more volatile than WAY relative to the S&P 500. On balance sheet safety, Waystar Holding Corp. (WAY) carries a lower debt/equity ratio of 39% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — WAY or HIMS or JPM?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Waystar Holding Corp. grew EPS 569. 2% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — WAY or HIMS or JPM?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus 5. 5% for Hims & Hers Health, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 4. 5% for HIMS. At the gross margin level — before operating expenses — HIMS leads at 73. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is WAY or HIMS or JPM more undervalued right now?

On forward earnings alone, Waystar Holding Corp.

(WAY) trades at 11. 4x forward P/E versus 14. 4x for JPMorgan Chase & Co. — 3. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WAY: 90. 0% to $35. 62.

08

Which pays a better dividend — WAY or HIMS or JPM?

In this comparison, JPM (1.

9% yield) pays a dividend. WAY, HIMS do not pay a meaningful dividend and should not be held primarily for income.

09

Is WAY or HIMS or JPM better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, HIMS: +173. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between WAY and HIMS and JPM?

These companies operate in different sectors (WAY (Technology) and HIMS (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WAY is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while WAY, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.